Literature DB >> 22160208

Upregulation of arginase-II contributes to decreased age-related myocardial contractile reserve.

Mehnaz Khan1, Jochen Steppan, Karl H Schuleri, Karl Schuleri, Sungwoo Ryoo, Eric Tuday, Lukasz Bugaj, Lakshmi Santhanam, Tal Berkowitz, Daniel Nyhan, Artin A Shoukas, Dan E Berkowitz.   

Abstract

Arginase-II (Arg-II) reciprocally regulates nitric oxide synthase (NOS) and offsets basal myocardial contractility. Furthermore, decreased or absent myocardial NOS activity is associated with a depression in myocardial contractile reserve. We therefore hypothesized that upregulation of Arg-II might in part be responsible for depressed myocardial contractility associated with age. We studied arginase activity/expression, NOS expression, NO production in the presence and absence of the arginase inhibitor S-(2-boronoethyl)-L: -cysteine (BEC) in old (22 months) and young (3 months) rat hearts and myocytes. The spatial confinement of Arg-II and NOS was determined with immuno-electron-miocrographic (IEM) and immuno-histochemical studies. We tested the effect of BEC on the force frequency response (FFR) in myocytes, as well as NOS abundance and activity. Arginase activity and Arg-II expression was increased in old hearts (2.27 ± 0.542 vs. 0.439 ± 0.058 nmol urea/mg protein, p = 0.02). This was associated with a decrease in NO production, which was restored with BEC (4.54 ± 0.582 vs. 12.88 ± 0.432 μmol/mg, p < 0.01). IEM illustrates increased mitochondrial density in old myocytes (51.7 ± 1.8 vs. 69 ± 2.2 × 10(6)/cm(2), p < 0.01), potentially contributing to increased Arg-II abundance and activity. Immunohistochemistry revealed an organized pattern of mitochondria and Arg-II that appears disrupted in old myocytes. The FFR was significantly depressed in old myocytes (61.42 ± 16.04 vs. -5.15 ± 5.65%), while inhibition of Arg-II restored the FFR (-5.15 ± 5.65 vs. 70.98 ± 6.10%). NOS-2 is upregulated sixfold in old hearts contributing to increased production of reactive oxygen species which is attenuated with NOS-2 inhibition by 1400 W (4,735 ± 427 vs. 4,014 ± 314 RFU/min/mg protein, p = 0.005). Arg-II upregulation in aging rat hearts contributes to age-related decreased contractile function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22160208     DOI: 10.1007/s00421-011-2257-9

Source DB:  PubMed          Journal:  Eur J Appl Physiol        ISSN: 1439-6319            Impact factor:   3.078


  33 in total

Review 1.  Nitrosylation. the prototypic redox-based signaling mechanism.

Authors:  J S Stamler; S Lamas; F C Fang
Journal:  Cell       Date:  2001-09-21       Impact factor: 41.582

2.  Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function.

Authors:  C Zhang; T W Hein; W Wang; C I Chang; L Kuo
Journal:  FASEB J       Date:  2001-05       Impact factor: 5.191

Review 3.  Aging and arterial stiffness.

Authors:  Hae-Young Lee; Byung-Hee Oh
Journal:  Circ J       Date:  2010-10-15       Impact factor: 2.993

4.  Nitroso-redox balance in the cardiovascular system.

Authors:  Joshua M Hare
Journal:  N Engl J Med       Date:  2004-11-08       Impact factor: 91.245

5.  Nitric oxide synthase isoform expression in a porcine model of granulation tissue formation.

Authors:  J S Pollock; W Webb; D Callaway; W O'Brien; T R Howdieshell
Journal:  Surgery       Date:  2001-03       Impact factor: 3.982

6.  Hypoxic upregulation of arginase II in human lung endothelial cells.

Authors:  Karina Krotova; Jawaharlal M Patel; Edward R Block; Sergey Zharikov
Journal:  Am J Physiol Cell Physiol       Date:  2010-09-22       Impact factor: 4.249

Review 7.  Protein S-nitrosylation: purview and parameters.

Authors:  Douglas T Hess; Akio Matsumoto; Sung-Oog Kim; Harvey E Marshall; Jonathan S Stamler
Journal:  Nat Rev Mol Cell Biol       Date:  2005-02       Impact factor: 94.444

8.  Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness.

Authors:  J M Hare; M M Givertz; M A Creager; W S Colucci
Journal:  Circulation       Date:  1998-01-20       Impact factor: 29.690

Review 9.  Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart.

Authors:  Soban Umar; Arnoud van der Laarse
Journal:  Mol Cell Biochem       Date:  2009-07-19       Impact factor: 3.396

10.  Endothelial arginase II: a novel target for the treatment of atherosclerosis.

Authors:  Sungwoo Ryoo; Gaurav Gupta; Alexandre Benjo; Hyun Kyo Lim; Andre Camara; Gautam Sikka; Hyun Kyung Lim; Jayson Sohi; Lakshmi Santhanam; Kevin Soucy; Eric Tuday; Ezra Baraban; Monica Ilies; Gary Gerstenblith; Daniel Nyhan; Artin Shoukas; David W Christianson; Nicholas J Alp; Hunter C Champion; David Huso; Dan E Berkowitz
Journal:  Circ Res       Date:  2008-02-28       Impact factor: 17.367

View more
  4 in total

1.  Arginase Inhibition Reverses Endothelial Dysfunction, Pulmonary Hypertension, and Vascular Stiffness in Transgenic Sickle Cell Mice.

Authors:  Jochen Steppan; Huong T Tran; Valeriani R Bead; Young Jun Oh; Gautam Sikka; Trinity J Bivalacqua; Arthur L Burnett; Dan E Berkowitz; Lakshmi Santhanam
Journal:  Anesth Analg       Date:  2016-09       Impact factor: 5.108

2.  Arginase-II Deficiency Extends Lifespan in Mice.

Authors:  Yuyan Xiong; Gautham Yepuri; Jean-Pierre Montani; Xiu-Fen Ming; Zhihong Yang
Journal:  Front Physiol       Date:  2017-09-08       Impact factor: 4.566

3.  Effects of arginase inhibition on myocardial Ca2+ and contractile responses.

Authors:  Jin Sun Cho; Young Soo Han; Cole Jensen; Gary Sieck
Journal:  Physiol Rep       Date:  2022-07

Review 4.  Arginase: shedding light on the mechanisms and opportunities in cardiovascular diseases.

Authors:  Zhuozhuo Li; Liwei Wang; Yuanyuan Ren; Yaoyao Huang; Wenxuan Liu; Ziwei Lv; Lu Qian; Yi Yu; Yuyan Xiong
Journal:  Cell Death Discov       Date:  2022-10-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.